Developing first-in-class drug candidates for alcohol intoxication and poisoning. Join us.
GOA Therapeutics is developing GOA26, a first-in-class drug candidate being designed to rapidly lower blood alcohol concentration. To our knowledge, there is no FDA-approved drug for acute alcohol intoxication and poisoning today.
.webp)
Investment highlights.
First-in-Class
The first drug candidate being designed to rapidly lower blood alcohol concentration.
Strong Patent Protection
A growing global intellectual property portfolio encompassing 30 patent applications owned.
To our knowledge, there is no FDA-approved drug to rapidly and safely eliminate alcohol from the body.
Clinicians can stabilize airways, administer fluids and monitor vital signs, but they cannot directly resolve the underlying intoxication. Today: no treatment and no plan.
Developing a therapy that can start acting in minutes, not hours.
A new approach to acute alcohol intoxication.
GOA26 is a two-stage combination drug candidate being designed to start acting in minutes, not hours. Stage 1: an enzyme metabolizes ethanol to acetaldehyde. Stage 2: a chemical formulation sequesters acetaldehyde. Being designed for trauma centers and emergency rooms, GOA26 is being built for the moments when waiting is not an option.
Acts at the source.
Designed to break down alcohol and neutralize its toxic metabolites directly in the bloodstream.
Designed to start acting within minutes, not hours.
IND-enabling preclinical studies in porcine models have been completed, supporting GOA26's advance toward first-in-human trials.
Rapid IV administration.
GOA26 is being developed initially for intravenous administration in acute-care medical settings, with potential for broader clinical applications over time.
Addressing a market with No FDA-Approved drug.
To our knowledge, there is currently no FDA-approved pharmacologic intervention addressing this unmet clinical need. GOA26 is aiming to be the first.
.webp)
Advancing toward first-in-human trials.
GOA26 has advanced through sophisticated protein engineering, formulation and manufacturing and successful IND-enabling testing in porcine models, progressing toward IND filing and clinical studies.
IND-enabling testing complete in porcine models.
Defined pathway toward IND filing and first-in-human clinical trials.
Protein engineering and manufacturing advanced.
GOA26 has advanced through sophisticated protein engineering, formulation and manufacturing.
30+ patents pending and approved globally.
GOA26 is protected by a growing global intellectual property portfolio.
Accepted for presentation.
GOA research is accepted for presentation by leading medical and scientific societies.
30+ Patents pending and approved globally.
GOA26 is a first-in-class drug candidate being developed to rapidly lower blood alcohol concentration. To our knowledge, there are no FDA-approved drugs for alcohol intoxication and poisoning today.
Exclusive Investor Perks
Phased commercialization strategy.
We have mapped a three-phase commercialization path to follow if GOA26 is approved for use. Initial focus on two clinical settings with the highest unmet need, expand to additional pre-hospital settings, and evaluate further applications over time. The model is projected to deliver high gross margins from day one, with US healthcare experts in primary market research indicating willingness to use GOA26 at a $2,500 price point.
Phase 1
Trauma centers and emergency rooms.
Highest acuity, highest need, fastest path to clinical adoption.
Phase 2
First responders, including ambulances and paramedics.
Expand deployment to pre-hospital emergency settings.
Phase 3
Broader applications beyond acute care.
Evaluate additional clinical applications and commercial opportunities over time.
Hundreds of years of combined biotech and healthcare leadership experience.
Our leadership team has contributed to the development and commercialization of multiple FDA-approved medicines.
Andrew Altschuler is the Co-Founder, President, CEO and Chairman of the Board of Directors of GOA Therapeutics. He oversees our company's strategic direction and operational leadership. With 30 years of professional experience, Andrew is a seasoned entrepreneur, patented inventor, investor, strategic advisor and Certified Public Accountant whose career has spanned the biotechnology, fintech, e-commerce, consumer goods, real estate and hospitality sectors. Throughout his entrepreneurial career Andrew has demonstrated a strong ability to identify new opportunities, build companies from the ground up and guide ventures through significant growth. Before founding GOA Therapeutics, Andrew devoted more than five years to strategic planning that laid the groundwork for its formation. Previously he worked in mergers and acquisitions advisory at Salomon Smith Barney, auditing at KPMG and Arthur Andersen, and wealth management at Merrill Lynch. Andrew earned a BBA in Accounting and an MPA in Financial Information Systems from the McCombs School of Business at the University of Texas at Austin. He has been a licensed Certified Public Accountant since 1998.
Dr. Tami Ehrmann Barr is the Co-Founder, Chief Scientific Officer and a member of the Board of Directors of GOA Therapeutics. She is a multidisciplinary expert with more than 40 years of experience driving innovation across the pharmaceuticals, biotechnology, medical devices, agrotechnology and advanced materials sectors. Dr. Ehrmann Barr is widely recognized for her ability to identify high-value scientific opportunities, design robust research and development programs and clinical and regulatory strategies and lead multidisciplinary teams developing innovative products. Her work includes significant contributions for leading institutions and international corporations including Novartis, NovoNordisk and Teva. She has held senior scientific and executive roles, including as Chief Scientific Officer, Chief Medical Officer, Chief Technology Officer and Head of Research and Development at companies including NanoDimension (NASDAQ: NNDM), CanFite Biopharma (NYSE: CANF), RDD Pharma (NASDAQ: NMTR), ADAMA (Shenzhen Stock Exchange: 000553), Ikigai Biotech, ESEV, Treat-It Innovative Therapeutics, OrthoTreat-It and BraiNose, among others. Her academic training includes an M.D. from the University of Cologne, a Ph.D. in Biotechnology and Microbiology from The Hebrew University of Jerusalem in collaboration with the Max Planck Institute in Cologne, a postdoctoral fellowship in Protein Engineering from the Max Planck Institute, an M.Sc. in Chemical and Medical Engineering from Ben-Gurion University of the Negev in collaboration with Soroka Hospital, a B.Sc. in Chemistry from The Hebrew University and an LL.B. in Law from Ono Academic College. She is the inventor of numerous patents spanning pharmaceuticals, bioprinting, nutraceutical formulations and medical technologies. Before founding GOA Therapeutics, she devoted more than a decade to exploratory research and development that shaped the company's scientific foundation.
Dr. Dean Hakanson is the Chief Medical Officer of GOA Therapeutics and brings more than 30 years of leadership experience across early-stage, IPO-driven and global biopharma organizations. His role at GOA is positioned around medical affairs, health economics and our commercialization strategy. A board-certified anesthesiologist with 15 years of clinical practice in trauma surgery and critical care, he integrates deep medical expertise with a proven ability to shape clinical development strategy, medical affairs, health economics and real-world evidence programs that support regulatory and commercial advancement. From 2023 until joining GOA in 2026, he served as a consultant to various healthcare-related clients. From 2020 to 2023, Dr. Hakanson served as Head of US Medical Affairs at Gilead, where he built the US Medical Affairs organization and guided the launch of Remdesivir, establishing it as the standard of care for hospitalized COVID-19 patients. From 2018 to 2020, he was Chief Medical Officer and Partner at ZS Associates, where he led global medical affairs, real-world evidence strategy and the firm's Medical Center of Excellence. From 2015 to 2018, he was Chief Medical Officer at Otonomy, overseeing clinical research, medical affairs, pharmacovigilance, regulatory engagement and the FDA approval and launch of OTIPRIO, the company's first approved product. Earlier in his career, he held roles at Novartis, Bristol Myers Squibb, Genentech and GlaxoSmithKline, contributing to value-based healthcare initiatives, payer engagement strategies and clinical evidence generation. Dr. Hakanson is widely regarded as a leader in health economics and policy and has served on the boards of the National Pharmaceutical Council and the USC Leonard D. Schaeffer Center for Health Policy and Economics. He is a Diplomate of the American Board of Anesthesiology and the American Medical Association. He earned his M.D. from the University of Colorado School of Medicine, completed anesthesiology residency training at the University of Michigan and UC Davis and graduated Phi Beta Kappa from the University of Denver with a BS in Cellular Physiology and Physics.
Dr. Scott Howell leads our efforts at the intersection of life sciences, healthcare delivery and market commercialization pathways. He is a nationally recognized expert on U.S. drug pricing, patient access and healthcare delivery. Dr. Howell joined GOA Therapeutics as Chief Commercial Officer in May 2026 on a fractional basis. Since May 2022 he has been founder and owner of Blue Line Advisors, LLC, a healthcare and biopharma advisory practice serving venture capital and private equity firms, health technology and AI companies, and both early-stage and established pharmaceutical companies, including GOA Therapeutics. Since September 2023 he has been a co-founder of Impossible Medicine, LLC, a fintech-enabled biopharma research sourcing, rating and investment platform and venture foundry. He has served on the board of directors of ADVI Health since January 2024 and as strategic advisor to Pear Venture Capital's biotech and health technology verticals since August 2023. From December 2020 to May 2022, Dr. Howell was Chief Strategy Officer and Head of US Business Development and Licensing for Novartis US Pharmaceuticals, and from June 2017 to December 2020 he was Senior Vice President and Head of US Market Access and Patient Services at Novartis. His earlier career includes senior leadership roles at Jazz Pharmaceuticals, Cardinal Health and Genentech, along with executive roles at Highmark Blue Cross Blue Shield and GlaxoSmithKline. He co-hosts the Prescription for Better Access podcast, a non-profit program on U.S. drug pricing and access, contributes frequently to leading academic and industry publications and served from 2024 to 2025 on a National Academy of Medicine consensus panel focused on improving U.S. drug research and development policy. He is a guest and professional lecturer at the University of California, Berkeley, Stanford, Columbia and The Ohio State University. Dr. Howell earned his B.S. with high honors from the University of Notre Dame and his M.D. magna cum laude from The Ohio State University, completed his internship and residency in internal medicine at Duke University Medical Center and earned his M.B.A. as a Fuqua Scholar from Duke University.
David Landesman is Chief Operating Officer of GOA Therapeutics, where he builds and runs the company's operational backbone: information technology, communications architecture, enterprise systems, and the infrastructure supporting the company's growth and financing activities.
A software engineer by background with over 18 years in engineering, system architecture, and technical strategy, David brings a systems-first approach to operations, pairing lean teams with AI-powered tooling and automation to drive velocity without adding headcount.
Over his career he has held senior leadership roles at technology companies, including Chief Technology Officer.
Dr. Iris Tam is Head of Medical Affairs & Health Economics and Outcomes Research (HEOR) at GOA Therapeutics, bringing 35 years of experience across medical affairs, market access, HEOR, managed care and clinical pharmacy.
Dr. Tam has held senior Medical Affairs leadership positions at Genentech, Otonomy and Achaogen, with responsibilities spanning health economics and outcomes research, medical communications, evidence generation, payer engagement, formulary and compendia strategy, and patient access. She previously served as Senior Vice President of Medical Affairs & HEOR at COEUS, where she led a business unit focused on evidence synthesis, HEOR strategy and payer communications.
Dr. Tam has been an active leader within the Academy of Managed Care Pharmacy (AMCP), including more than a decade of service on the AMCP Format Executive Committee, and is a Fellow of the Academy of Managed Care Pharmacy. She has also received AMCP's Spirit of Volunteerism Award for her contributions to the profession.
Dr. Tam earned her Doctor of Pharmacy from the University of California, San Francisco and her bachelor's degree in Microbiology and Immunology from the University of California, Berkeley. She subsequently completed residencies in Clinical Pharmacy Practice and Pharmacy Administration at California Pacific Medical Center in San Francisco.